{
  "success": true,
  "pagesUsed": [
    1,
    11,
    15,
    17,
    23,
    27
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "Background",
        "text": "Background",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "Background",
        "sectionType": {
          "id": "16a38003-1ccd-496e-82fe-d5034f21ed49",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_1_1",
          "nci_1_2",
          "nci_1_3",
          "nci_1_4"
        ]
      },
      {
        "id": "nc_2",
        "name": "Rationale",
        "text": "Rationale",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "Rationale",
        "sectionType": {
          "id": "72dcb23b-7829-4346-b7af-992972c391d6",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3",
          "nci_2_4",
          "nci_2_5",
          "nci_2_6",
          "nci_2_7"
        ]
      },
      {
        "id": "nc_3",
        "name": "Objectives and endpoints",
        "text": "Objectives and endpoints",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "Objectives and endpoints",
        "sectionType": {
          "id": "773719b1-dc51-4992-99f9-7671bfd943c7",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "Study design",
        "text": "Study design",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "Study design",
        "sectionType": {
          "id": "ec315d8b-e3ce-44c0-8f92-1a9f9baf596a",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4",
          "nci_4_5",
          "nci_4_6",
          "nci_4_7"
        ]
      },
      {
        "id": "nc_5",
        "name": "Treatment",
        "text": "Treatment",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "6",
        "sectionTitle": "Treatment",
        "sectionType": {
          "id": "dfaf0f49-8508-465e-8abc-076366920c05",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2"
        ]
      },
      {
        "id": "nc_6",
        "name": "Study Procedures and Assessments",
        "text": "Study Procedures and Assessments",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "7",
        "sectionTitle": "Study Procedures and Assessments",
        "sectionType": {
          "id": "8503dbb2-5a65-42ab-97f4-4357c4a02b4e",
          "code": "Assessments",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Assessments",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2",
          "nci_6_3",
          "nci_6_4"
        ]
      },
      {
        "id": "nc_7",
        "name": "Safety Monitoring and Reporting",
        "text": "Safety Monitoring and Reporting",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "8",
        "sectionTitle": "Safety Monitoring and Reporting",
        "sectionType": {
          "id": "5734f6e6-39bf-4fbb-a083-1c63aa3f84ed",
          "code": "Safety",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Safety",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_7_1",
          "nci_7_2"
        ]
      },
      {
        "id": "nc_8",
        "name": "Statistical methods and data analysis",
        "text": "Statistical methods and data analysis",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10",
        "sectionTitle": "Statistical methods and data analysis",
        "sectionType": {
          "id": "53b854f9-8b83-41fb-8cf8-5f20928b4ee4",
          "code": "Statistics",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Statistics",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_8_1",
          "nci_8_2"
        ]
      },
      {
        "id": "nc_9",
        "name": "References",
        "text": "References",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "13",
        "sectionTitle": "References",
        "sectionType": {
          "id": "ddfa713e-986a-4619-a4ba-775d4a529c8a",
          "code": "References",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "References",
          "instanceType": "Code"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_1_1",
        "name": "Overview of disease pathogenesis, epidemiology and current treatment",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Overview of disease pathogenesis, epidemiology and current treatment"
      },
      {
        "id": "nci_1_2",
        "name": "Introduction to investigational treatment(s) and other study treatment(s)",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Introduction to investigational treatment(s) and other study treatment(s)"
      },
      {
        "id": "nci_1_3",
        "name": "Overview of PDR001",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.1",
        "sectionTitle": "Overview of PDR001"
      },
      {
        "id": "nci_1_4",
        "name": "Overview of dabrafenib and trametinib",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2.2",
        "sectionTitle": "Overview of dabrafenib and trametinib"
      },
      {
        "id": "nci_2_1",
        "name": "Study rationale and purpose",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Study rationale and purpose"
      },
      {
        "id": "nci_2_2",
        "name": "Rationale for the study design",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Rationale for the study design"
      },
      {
        "id": "nci_2_3",
        "name": "Rationale for dose and regimen selection",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.3",
        "sectionTitle": "Rationale for dose and regimen selection"
      },
      {
        "id": "nci_2_4",
        "name": "Rationale for choice of combination drugs",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.4",
        "sectionTitle": "Rationale for choice of combination drugs"
      },
      {
        "id": "nci_2_5",
        "name": "Rationale for choice of comparator drugs",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.5",
        "sectionTitle": "Rationale for choice of comparator drugs"
      },
      {
        "id": "nci_2_6",
        "name": "Risks and benefits",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.6",
        "sectionTitle": "Risks and benefits"
      },
      {
        "id": "nci_2_7",
        "name": "Rationale for public health emergency mitigation procedures",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.7",
        "sectionTitle": "Rationale for public health emergency mitigation procedures"
      },
      {
        "id": "nci_4_1",
        "name": "Description of study design",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "Description of study design"
      },
      {
        "id": "nci_4_2",
        "name": "Screening phase",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.1",
        "sectionTitle": "Screening phase"
      },
      {
        "id": "nci_4_3",
        "name": "Treatment phase",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.2",
        "sectionTitle": "Treatment phase"
      },
      {
        "id": "nci_4_4",
        "name": "End of treatment",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.3",
        "sectionTitle": "End of treatment"
      },
      {
        "id": "nci_4_5",
        "name": "Safety follow-up",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.4",
        "sectionTitle": "Safety follow-up"
      },
      {
        "id": "nci_4_6",
        "name": "Efficacy follow-up",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1.5",
        "sectionTitle": "Efficacy follow-up"
      },
      {
        "id": "nci_4_7",
        "name": "Timing of interim analyses and design adaptations",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "Timing of interim analyses and design adaptations"
      },
      {
        "id": "nci_5_1",
        "name": "PTA information and procedures",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.1.5",
        "sectionTitle": "PTA information and procedures"
      },
      {
        "id": "nci_5_2",
        "name": "Reference of AEs and toxicity management guidelines",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.3",
        "sectionTitle": "Reference of AEs and toxicity management guidelines"
      },
      {
        "id": "nci_6_1",
        "name": "Visit evaluation schedule",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "7.1",
        "sectionTitle": "Visit evaluation schedule"
      },
      {
        "id": "nci_6_2",
        "name": "Central review of imaging data",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "7.2.1",
        "sectionTitle": "Central review of imaging data"
      },
      {
        "id": "nci_6_3",
        "name": "Biomarkers",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "7.2.4",
        "sectionTitle": "Biomarkers"
      },
      {
        "id": "nci_6_4",
        "name": "Patient reported outcomes",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "7.2.5",
        "sectionTitle": "Patient reported outcomes"
      },
      {
        "id": "nci_7_1",
        "name": "Emergency unblinding of treatment assignment",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.3",
        "sectionTitle": "Emergency unblinding of treatment assignment"
      },
      {
        "id": "nci_7_2",
        "name": "Pregnancies",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.4",
        "sectionTitle": "Pregnancies"
      },
      {
        "id": "nci_8_1",
        "name": "Key secondary objectives",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.5.1",
        "sectionTitle": "Key secondary objectives"
      },
      {
        "id": "nci_8_2",
        "name": "Overall survival",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.7.2",
        "sectionTitle": "Overall survival"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "ADA",
        "expandedText": "Anti-Drug Antibodies",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "ADL",
        "expandedText": "Activities of Daily Living",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "AE",
        "expandedText": "Adverse Event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "AESI",
        "expandedText": "Adverse Events of Special Interest",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "AJCC",
        "expandedText": "American Joint Committee on Cancer",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "ALT",
        "expandedText": "Alanine Aminotransferase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "AST",
        "expandedText": "Aspartate Aminotransferase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "ATC",
        "expandedText": "Anatomical Therapeutic Chemical",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "AUC",
        "expandedText": "Area Under the Concentration-time Curve",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "AV",
        "expandedText": "Atrioventricular",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "BID",
        "expandedText": "bis in diem/twice a day",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "BLQ",
        "expandedText": "Below Limit of Quantification",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "BLRM",
        "expandedText": "Bayesian Logistic Regression Model",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "BP",
        "expandedText": "Blood Pressure",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "BUN",
        "expandedText": "Blood Urea Nitrogen",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "CD4",
        "expandedText": "Cluster of Differentiation 4",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "CD8",
        "expandedText": "Cluster of Differentiation 8",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "CI",
        "expandedText": "Confidence interval",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "Cmax",
        "expandedText": "Maximum Concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "CMO&PS",
        "expandedText": "Chief Medical Office and Patient Safety",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "CNS",
        "expandedText": "Central Nervous System",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "COVID-19",
        "expandedText": "Coronavirus disease-19",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "CT",
        "expandedText": "Computed Tomography",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "CRF",
        "expandedText": "Case Report/Record Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "CRO",
        "expandedText": "Contract Research Organization",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "CRP",
        "expandedText": "C-Reactive Protein",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "CSP",
        "expandedText": "Clinical Study Protocol",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "CSR",
        "expandedText": "Clinical Study Report",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "CTCAE",
        "expandedText": "Common Terminology Criteria for Adverse Events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "CTLA-4",
        "expandedText": "Cytotoxic T Lymphocyte Antigen 4",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "CV",
        "expandedText": "Coefficient of Variation",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "CYP",
        "expandedText": "Cytochromes P450",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_33",
        "abbreviatedText": "D + T",
        "expandedText": "Dabrafenib and trametinib",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_34",
        "abbreviatedText": "D5W",
        "expandedText": "Dextrose 5% in Water",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_35",
        "abbreviatedText": "DAR",
        "expandedText": "Dosage Administration Record",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_36",
        "abbreviatedText": "DBP",
        "expandedText": "Diastolic Blood Pressure",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_37",
        "abbreviatedText": "DCO",
        "expandedText": "Data cut-off",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_38",
        "abbreviatedText": "DCR",
        "expandedText": "Disease Control Rate",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_39",
        "abbreviatedText": "DDI",
        "expandedText": "Drug-Drug Interaction",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_40",
        "abbreviatedText": "DDS",
        "expandedText": "Dose-Determining Set",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_41",
        "abbreviatedText": "DILI",
        "expandedText": "Drug Induced Liver Injury",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_42",
        "abbreviatedText": "DL",
        "expandedText": "Dose Level",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_43",
        "abbreviatedText": "DLRT",
        "expandedText": "Dose Level Review Team",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_44",
        "abbreviatedText": "PTA",
        "expandedText": "Post-Trial Access",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_45",
        "abbreviatedText": "PSDS",
        "expandedText": "post study drug supply",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_46",
        "abbreviatedText": "HLH",
        "expandedText": "hemophagocytic lymphohistiocytosis",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_47",
        "abbreviatedText": "MHRA",
        "expandedText": "UK Health Authority",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_48",
        "abbreviatedText": "PK",
        "expandedText": "Pharmacokinetics",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_49",
        "abbreviatedText": "IG",
        "expandedText": "Immunogenicity",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_50",
        "abbreviatedText": "RECIST 1.1",
        "expandedText": "Response Evaluation Criteria in Solid Tumors",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_51",
        "abbreviatedText": "PRO",
        "expandedText": "Patient reported outcomes",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_52",
        "abbreviatedText": "PFS",
        "expandedText": "progression-free survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_53",
        "abbreviatedText": "OS",
        "expandedText": "overall survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_54",
        "abbreviatedText": "SAE",
        "expandedText": "Serious Adverse Events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_55",
        "abbreviatedText": "IWRS",
        "expandedText": "Interactive Web Response System",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_56",
        "abbreviatedText": "DMC",
        "expandedText": "Data Monitoring Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_57",
        "abbreviatedText": "IRB",
        "expandedText": "Institutional Review Board",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_58",
        "abbreviatedText": "IEC",
        "expandedText": "Independent Ethics Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_59",
        "abbreviatedText": "ECG",
        "expandedText": "Electrocardiogram",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 9,
      "itemCount": 28,
      "abbreviationCount": 59
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of PDR001 in Combination with Dabrafenib and Trametinib in Patients with Previously Untreated BRAF V600-mutant Unresectable or Metastatic Melanoma",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "07 (Clean)",
      "versionDate": "27-Jan-2023",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "ADA",
          "expansion": "Anti-Drug Antibodies"
        },
        {
          "abbreviation": "ADL",
          "expansion": "Activities of Daily Living"
        },
        {
          "abbreviation": "AE",
          "expansion": "Adverse Event"
        },
        {
          "abbreviation": "AESI",
          "expansion": "Adverse Events of Special Interest"
        },
        {
          "abbreviation": "AJCC",
          "expansion": "American Joint Committee on Cancer"
        },
        {
          "abbreviation": "ALT",
          "expansion": "Alanine Aminotransferase"
        },
        {
          "abbreviation": "AST",
          "expansion": "Aspartate Aminotransferase"
        },
        {
          "abbreviation": "ATC",
          "expansion": "Anatomical Therapeutic Chemical"
        },
        {
          "abbreviation": "AUC",
          "expansion": "Area Under the Concentration-time Curve"
        },
        {
          "abbreviation": "AV",
          "expansion": "Atrioventricular"
        },
        {
          "abbreviation": "BID",
          "expansion": "bis in diem/twice a day"
        },
        {
          "abbreviation": "BLQ",
          "expansion": "Below Limit of Quantification"
        },
        {
          "abbreviation": "BLRM",
          "expansion": "Bayesian Logistic Regression Model"
        },
        {
          "abbreviation": "BP",
          "expansion": "Blood Pressure"
        },
        {
          "abbreviation": "BUN",
          "expansion": "Blood Urea Nitrogen"
        },
        {
          "abbreviation": "CD4",
          "expansion": "Cluster of Differentiation 4"
        },
        {
          "abbreviation": "CD8",
          "expansion": "Cluster of Differentiation 8"
        },
        {
          "abbreviation": "CI",
          "expansion": "Confidence interval"
        },
        {
          "abbreviation": "Cmax",
          "expansion": "Maximum Concentration"
        },
        {
          "abbreviation": "CMO&PS",
          "expansion": "Chief Medical Office and Patient Safety"
        },
        {
          "abbreviation": "CNS",
          "expansion": "Central Nervous System"
        },
        {
          "abbreviation": "COVID-19",
          "expansion": "Coronavirus disease-19"
        },
        {
          "abbreviation": "CT",
          "expansion": "Computed Tomography"
        },
        {
          "abbreviation": "CRF",
          "expansion": "Case Report/Record Form"
        },
        {
          "abbreviation": "CRO",
          "expansion": "Contract Research Organization"
        },
        {
          "abbreviation": "CRP",
          "expansion": "C-Reactive Protein"
        },
        {
          "abbreviation": "CSP",
          "expansion": "Clinical Study Protocol"
        },
        {
          "abbreviation": "CSR",
          "expansion": "Clinical Study Report"
        },
        {
          "abbreviation": "CTCAE",
          "expansion": "Common Terminology Criteria for Adverse Events"
        },
        {
          "abbreviation": "CTLA-4",
          "expansion": "Cytotoxic T Lymphocyte Antigen 4"
        },
        {
          "abbreviation": "CV",
          "expansion": "Coefficient of Variation"
        },
        {
          "abbreviation": "CYP",
          "expansion": "Cytochromes P450"
        },
        {
          "abbreviation": "D + T",
          "expansion": "Dabrafenib and trametinib"
        },
        {
          "abbreviation": "D5W",
          "expansion": "Dextrose 5% in Water"
        },
        {
          "abbreviation": "DAR",
          "expansion": "Dosage Administration Record"
        },
        {
          "abbreviation": "DBP",
          "expansion": "Diastolic Blood Pressure"
        },
        {
          "abbreviation": "DCO",
          "expansion": "Data cut-off"
        },
        {
          "abbreviation": "DCR",
          "expansion": "Disease Control Rate"
        },
        {
          "abbreviation": "DDI",
          "expansion": "Drug-Drug Interaction"
        },
        {
          "abbreviation": "DDS",
          "expansion": "Dose-Determining Set"
        },
        {
          "abbreviation": "DILI",
          "expansion": "Drug Induced Liver Injury"
        },
        {
          "abbreviation": "DL",
          "expansion": "Dose Level"
        },
        {
          "abbreviation": "DLRT",
          "expansion": "Dose Level Review Team"
        },
        {
          "abbreviation": "PTA",
          "expansion": "Post-Trial Access"
        },
        {
          "abbreviation": "PSDS",
          "expansion": "post study drug supply"
        },
        {
          "abbreviation": "HLH",
          "expansion": "hemophagocytic lymphohistiocytosis"
        },
        {
          "abbreviation": "MHRA",
          "expansion": "UK Health Authority"
        },
        {
          "abbreviation": "PK",
          "expansion": "Pharmacokinetics"
        },
        {
          "abbreviation": "IG",
          "expansion": "Immunogenicity"
        },
        {
          "abbreviation": "RECIST 1.1",
          "expansion": "Response Evaluation Criteria in Solid Tumors"
        },
        {
          "abbreviation": "PRO",
          "expansion": "Patient reported outcomes"
        },
        {
          "abbreviation": "PFS",
          "expansion": "progression-free survival"
        },
        {
          "abbreviation": "OS",
          "expansion": "overall survival"
        },
        {
          "abbreviation": "SAE",
          "expansion": "Serious Adverse Events"
        },
        {
          "abbreviation": "IWRS",
          "expansion": "Interactive Web Response System"
        },
        {
          "abbreviation": "DMC",
          "expansion": "Data Monitoring Committee"
        },
        {
          "abbreviation": "IRB",
          "expansion": "Institutional Review Board"
        },
        {
          "abbreviation": "IEC",
          "expansion": "Independent Ethics Committee"
        },
        {
          "abbreviation": "ECG",
          "expansion": "Electrocardiogram"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of PDR001 in Combination with Dabrafenib and Trametinib in Patients with Previously Untreated BRAF V600-mutant Unresectable or Metastatic Melanoma",
        "version": "07 (Clean)",
        "versionDate": "27-Jan-2023"
      },
      "sections": [
        {
          "number": "1",
          "title": "Background",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Overview of disease pathogenesis, epidemiology and current treatment"
            },
            {
              "number": "1.2",
              "title": "Introduction to investigational treatment(s) and other study treatment(s)"
            },
            {
              "number": "1.2.1",
              "title": "Overview of PDR001"
            },
            {
              "number": "1.2.2",
              "title": "Overview of dabrafenib and trametinib"
            }
          ]
        },
        {
          "number": "2",
          "title": "Rationale",
          "type": "Other",
          "subsections": [
            {
              "number": "2.1",
              "title": "Study rationale and purpose"
            },
            {
              "number": "2.2",
              "title": "Rationale for the study design"
            },
            {
              "number": "2.3",
              "title": "Rationale for dose and regimen selection"
            },
            {
              "number": "2.4",
              "title": "Rationale for choice of combination drugs"
            },
            {
              "number": "2.5",
              "title": "Rationale for choice of comparator drugs"
            },
            {
              "number": "2.6",
              "title": "Risks and benefits"
            },
            {
              "number": "2.7",
              "title": "Rationale for public health emergency mitigation procedures"
            }
          ]
        },
        {
          "number": "3",
          "title": "Objectives and endpoints",
          "type": "Objectives"
        },
        {
          "number": "4",
          "title": "Study design",
          "type": "Study Design",
          "subsections": [
            {
              "number": "4.1",
              "title": "Description of study design"
            },
            {
              "number": "4.1.1",
              "title": "Screening phase"
            },
            {
              "number": "4.1.2",
              "title": "Treatment phase"
            },
            {
              "number": "4.1.3",
              "title": "End of treatment"
            },
            {
              "number": "4.1.4",
              "title": "Safety follow-up"
            },
            {
              "number": "4.1.5",
              "title": "Efficacy follow-up"
            },
            {
              "number": "4.2",
              "title": "Timing of interim analyses and design adaptations"
            }
          ]
        },
        {
          "number": "6",
          "title": "Treatment",
          "type": "Treatment",
          "subsections": [
            {
              "number": "6.1.5",
              "title": "PTA information and procedures"
            },
            {
              "number": "6.3",
              "title": "Reference of AEs and toxicity management guidelines"
            }
          ]
        },
        {
          "number": "7",
          "title": "Study Procedures and Assessments",
          "type": "Assessments",
          "subsections": [
            {
              "number": "7.1",
              "title": "Visit evaluation schedule"
            },
            {
              "number": "7.2.1",
              "title": "Central review of imaging data"
            },
            {
              "number": "7.2.4",
              "title": "Biomarkers"
            },
            {
              "number": "7.2.5",
              "title": "Patient reported outcomes"
            }
          ]
        },
        {
          "number": "8",
          "title": "Safety Monitoring and Reporting",
          "type": "Safety",
          "subsections": [
            {
              "number": "8.3",
              "title": "Emergency unblinding of treatment assignment"
            },
            {
              "number": "8.4",
              "title": "Pregnancies"
            }
          ]
        },
        {
          "number": "10",
          "title": "Statistical methods and data analysis",
          "type": "Statistics",
          "subsections": [
            {
              "number": "10.5.1",
              "title": "Key secondary objectives"
            },
            {
              "number": "10.7.2",
              "title": "Overall survival"
            }
          ]
        },
        {
          "number": "13",
          "title": "References",
          "type": "References"
        }
      ]
    }
  }
}